These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1459797)

  • 1. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon.
    Marasini B; Cugno M; Bassani C; Stanzani M; Bottasso B; Agostoni A
    Int J Microcirc Clin Exp; 1992 Nov; 11(4):375-82. PubMed ID: 1459797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of early endothelial damage in patients with Raynaud's phenomenon.
    Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Borghi MO; Bucciarelli P; Meroni PL; Cugno M
    Microvasc Res; 2017 Sep; 113():22-28. PubMed ID: 28450106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.
    Herrick AL; Illingworth K; Blann A; Hay CR; Hollis S; Jayson MI
    Ann Rheum Dis; 1996 Feb; 55(2):122-7. PubMed ID: 8712862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of tumor necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud's phenomenon.
    Cimminiello C; Arpaia G; Toschi V; Rossi F; Aloisio M; Motta A; Bonfardeci G
    Angiology; 1994 Dec; 45(12):1015-22. PubMed ID: 7985828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon.
    Marasini B; Casari S; Bestetti A; Maioli C; Cugno M; Zeni S; Turri O; Guagnellini E; Biondi ML
    J Rheumatol; 2000 Nov; 27(11):2621-3. PubMed ID: 11093443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.
    Kahaleh MB; Osborn I; LeRoy EC
    Ann Intern Med; 1981 Apr; 94(4 pt 1):482-4. PubMed ID: 6782927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of von Willebrand factor and plasminogen activator in patients with arterial thromboembolism--with special reference to their correlation to the increased catabolism of both fibrinogen and platelets.
    Matsumoto M; Uchiyama T; Kobayashi N; Maekawa T
    Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1105-14. PubMed ID: 2588960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
    Wieczorek I; Ludlam CA; MacGregor IR
    Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.
    Lau CS; McLaren M; Mackay I; Belch JJ
    Ann Rheum Dis; 1993 Jun; 52(6):443-8. PubMed ID: 8323396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of beraprost sodium on the Raynaud's phenomenon].
    Hiida M; Ushiyama O; Suzuki N; Ohta A; Nagasawa K; Yamaguchi M
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Jun; 19(3):193-200. PubMed ID: 8810544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CENP-B and anti-TOPO-1-containing sera from systemic sclerosis-related diseases with Raynaud's phenomenon induce vascular endothelial cell senescence not via classical p53-p21 pathway.
    Shen CY; Li KJ; Lai PH; Yu CL; Hsieh SC
    Clin Rheumatol; 2018 Mar; 37(3):749-756. PubMed ID: 28940121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
    Li Y; Chen H; Tan J; Wang X; Liang H; Sun X
    Eur J Clin Invest; 1998 Dec; 28(12):1050-4. PubMed ID: 9893018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis.
    Silveri F; De Angelis R; Poggi A; Muti S; Bonapace G; Argentati F; Cervini C
    Scand J Rheumatol; 2001; 30(5):290-6. PubMed ID: 11727844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon.
    Blann AD; Illingworth K; Jayson MI
    J Rheumatol; 1993 Aug; 20(8):1325-30. PubMed ID: 8230013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial haemostatic markers in members of families with familial combined hyperlipidemia.
    Karásek D; Vaverková H; Halenka M; Slavík L; Novotný D
    Thromb Res; 2009; 123(3):466-75. PubMed ID: 18417194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon.
    Lau CS; McLaren M; Belch JJ
    Br J Rheumatol; 1991 Dec; 30(6):433-6. PubMed ID: 1747698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning.
    van Kesteren PJ; Kooistra T; Lansink M; van Kamp GJ; Asscheman H; Gooren LJ; Emeis JJ; Vischer UM; Stehouwer CD
    Thromb Haemost; 1998 May; 79(5):1029-33. PubMed ID: 9609242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon.
    Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Sottilotta G; Larosa D; Barbera N
    Panminerva Med; 2000 Mar; 42(1):7-9. PubMed ID: 11019597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.